Last reviewed · How we verify
aspirin + clopidogrel + celecoxib
This combination inhibits platelet aggregation through multiple pathways (cyclooxygenase and P2Y12 receptor blockade) while also reducing inflammation via COX-2 inhibition.
This combination inhibits platelet aggregation through multiple pathways (cyclooxygenase and P2Y12 receptor blockade) while also reducing inflammation via COX-2 inhibition. Used for Acute coronary syndrome or post-percutaneous coronary intervention (dual antiplatelet therapy with anti-inflammatory component).
At a glance
| Generic name | aspirin + clopidogrel + celecoxib |
|---|---|
| Also known as | aspirin : Keun-Hwa Phamaceutical, clopidogrel : sanofi-aventis, celecoxib : Pfizer |
| Sponsor | Seoul National University Hospital |
| Drug class | Antiplatelet agent combination with NSAID |
| Target | COX-1, P2Y12 receptor, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), blocking thromboxane A2 production and platelet aggregation. Clopidogrel is a P2Y12 receptor antagonist that prevents ADP-induced platelet activation. Celecoxib selectively inhibits COX-2, providing anti-inflammatory and analgesic effects. Together, these agents provide dual antiplatelet therapy with added anti-inflammatory benefit.
Approved indications
- Acute coronary syndrome or post-percutaneous coronary intervention (dual antiplatelet therapy with anti-inflammatory component)
Common side effects
- Bleeding/hemorrhage
- Gastrointestinal bleeding
- Dyspepsia
- Thrombotic thrombocytopenic purpura (clopidogrel-related)
Key clinical trials
- Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers
- The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers (PHASE4)
- Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: